M
MNPR
Monopar Therapeutics Inc
78.96
-5.02-5.98%After Hours: 77.87 -1.09 -1.38%19:32 10/09 EDT
OPEN/PREV CLOSE83.47/83.98
TODAY RANGE78.80-84.04
VOL135.85K
MARKET CAP529.99M
52 WEEK RANGE50.07-124.82
AVG VOL (3M)213.16K
% TURNOVER1.79%
TURNOVER--
P/E (TTM)-36.3871
% RANGE6.14%
EPS(TTM)-2.1700
P/E(FORWARD)-31.8387
P/B4.050
BVPS19.50
DIVIDEND--
P/S0.3839
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP392.76M
SHARES OUTSTANDING6.71M
NEXT EARNINGS11/11-11/16
FREE FLOAT4.97M
LOT SIZE1
EX-DATE08/13/2024
News
Press Releases
Financial Reports
Profile
TipRanks·09/28 12:07
Piper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)
TipRanks·09/22 09:45
H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
Dow Jones·09/11 13:58
Monopar Therapeutics Is Maintained at Overweight by Barclays
TipRanks·09/11 09:30
Monopar Therapeutics price target raised to $145 from $128 at Barclays
Seeking Alpha·08/18 15:45
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
TipRanks·08/17 13:11
Monopar Therapeutics price target raised to $130 from $115 at Morgan Stanley
TipRanks·08/17 12:57
Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
TipRanks·08/17 08:35
Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
TipRanks·08/17 08:30
Monopar Therapeutics price target raised to $128 from $125 at Barclays
Seeking Alpha·08/13 17:11
Monopar cut to Neutral at Cantor on valuation
Benzinga·08/13 16:09
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Dow Jones·08/13 14:31
Monopar Therapeutics Is Maintained at Overweight by Barclays
Same Industry